|1.||Zhang, Manchao: 2 articles (07/2007 - 01/2007)|
|2.||Wang, Shaomeng: 2 articles (07/2007 - 01/2007)|
|3.||Liu, Hongpeng: 2 articles (07/2007 - 01/2007)|
|4.||Yang, Dajun: 2 articles (07/2007 - 01/2007)|
|5.||Fang, Xueliang: 2 articles (07/2007 - 01/2007)|
|6.||Wu, Xiaojin: 1 article (07/2007)|
|7.||Guo, Ribo: 1 article (07/2007)|
|8.||Zhu, Feng: 1 article (07/2007)|
|9.||Ling, Yan: 1 article (07/2007)|
|10.||Griffith, Brian N: 1 article (07/2007)|
|1.||Brain Neoplasms (Brain Tumor)
07/01/1995 - "Statistically significant effects and individual long-term survivors were observed in two experiments; These results provide support for the further preclinical development of 9-chloro-2-methylellipticinium acetate as a candidate for clinical trials against human brain cancer."
07/01/1995 - "Therapeutic activity of 9-chloro-2-methylellipticinium acetate in an orthotopic model of human brain cancer."
01/01/1998 - "Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts."
|2.||Prostatic Neoplasms (Prostate Cancer)
01/01/2007 - "Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP)."
01/01/2007 - "The inhibitory effects of a potent and selective AKT/BKB small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP), on the activation of AKT, its antiproliferation and apoptosis-inducing effects in prostate cancer cell lines: DU-145, PC-3, LNCaP, and CL-1, an androgen-independent LNCaP variant, and CL-1 xenograft mouse model were assessed by Western blot analysis, kinase assay, cell survival assay, and apoptosis assay in this report. "
|3.||Breast Neoplasms (Breast Cancer)
|1.||Heterologous Transplantation (Xenotransplantation)